PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($0.82), $0.22 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $45.03 million.

2017 Guidance:

• Translarna net sales guidance for 2017 is anticipated to be between $120 and $140 million. We now anticipate EMFLAZA net sales for 2017 to be between $20 and $25 million, an increase from our prior guidance of $15 to $20 million. This brings 2017 full year revenue guidancebetween $160 and $185 million, an increase from our prior guidance of $155 million to $180 million, including a $20 million milestone we achieved in mid-October, under our SMA program.
• GAAP R&D and SG&A expense for the full year 2017 are now anticipated to be between $250 to $260 million. Excluding estimated non-cash, stock-based compensation expense of approximately $40 million, full year 2017 non-GAAP R&D and SG&A expense are now anticipated to be between $210 million and $220 million. These expenses will be primarily in support of the commercial availability of Translarna globally, the commercial launch of EMFLAZA in the U.S. and the continued research and clinical development of other product pipeline candidates.
• We now expect to end 2017 with over $150 million of cash and cash equivalents, an increase from prior guidance of $120 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.